Breaking News
Moderna
About Moderna
At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.
We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. Since our founding in 2010, we have worked to build the industry’s leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team.
Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic. In addition, we have numerous discovery programs advancing toward development. Headquartered in Cambridge, Mass., privately held Moderna currently has strategic relationships with AstraZeneca, Plc. (AZ), Merck, Inc (MRK) and Vertex Pharmaceuticals (VRTX), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS); and the Bill & Melinda Gates Foundation. In 2017 Moderna was ranked a top biopharma industry employer by Science Magazine and a Top Place to Work by the Boston Globe.
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
February 3 2023
Personalis, a leader in advanced genomics for precision oncology, and Moderna, a biotechnology company pioneering […]
Swissmedic Authorizes Moderna’s Omicron-targeting Bivalent Booster Candidate, mRNA-1273.214
August 30 2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
James Mock Joins Moderna as Chief Financial Officer
August 19 2022
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Medicines and Healthcare Products Regulatory Agency (MHRA) Authorizes Moderna's Omicron-containing Bivalent Booster in the UK
August 17 2022
Moderna, Inc . (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna and the European Commission (EC) Amend Covid-19 Vaccine Agreement to Supply Omicron-containing Bivalent Candidates; EC Purchases Additional 15 Million Doses
August 11 2022
Moderna, Inc.(NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced an […]
EMA Committee for Medicinal Products for Human Use (CHMP) Recommends Use of the Moderna COVID-19 Booster in Adolescents (12-17 Years) in the European Union
July 26 2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that […]
Moderna's Omicron-containing Bivalent Booster Candidate, mRNA-1273.214, Demonstrates Significantly Higher Neutralizing Antibody Response Against Omicron Subvariants BA.4/5 Compared to Currently Authorized Booster
July 14 2022
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces First Participant Dosed in a Phase 1 Trial of Its Nipah Virus mRNA Vaccine, mRNA-1215
July 14 2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces Bivalent Booster mRNA -1273.214 Demonstrates Potent Neutralizing Antibody Response Against Omicron Subvariants Ba.4 and Ba.5
June 24 2022
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces Plan to Bring mRNA Innovation to the United Kingdom
June 22 2022
Moderna, Inc . (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces Omicron-containing Bivalent Booster Candidate Mrna-1273.214 Demonstrates Superior Antibody Response Against Omicron
June 10 2022
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program
May 20 2022
The nonprofit scientific research organization IAVI and Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger […]
Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day
May 19 2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messengerRNA (mRNA) therapeutics and vaccines, today announced new […]
Arpa Garay Joins Moderna as Chief Commercial Officer
April 28 2022
Moderna, Inc., (NASDAQ:MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna and Thermo Fisher Scientific Announce Long-term Strategic Collaboration
February 24 2022
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and […]
Moderna Expands its mRNA Pipeline with Three New Development Programs
February 21 2022
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
January 28 2022
IAVI, the nonprofit scientific research organization, and biotechnology company Moderna announced today that first doses […]
Moderna Announces Supply Agreement with the UK for Additional 60 Million Doses of Moderna’s COVID-19 Vaccine in 2022 and 2023
December 3 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
November 29 2021
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces EU and EEA Countries to Donate More than 70 Million Doses of Moderna COVID-19 Vaccine to Help End COVID-19 Pandemic in Low Income Countries
November 16 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
October 14 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year
October 8 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
October 6 2021
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today […]
Moderna and Canada Announce Collaboration to Bring mRNA Manufacturing to Canada
August 11 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Dr. Paul Burton to Join Moderna as Chief Medical Officer
June 15 2021
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union
June 8 2021
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
UNICEF and Moderna Announce Long Term Agreement to Supply Vaccine on Behalf of the COVAX Facility
June 2 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and UNICEF today announced […]
Moderna Announces TeenCOVE Study of COVID-19 Vaccine (mRNA-1273) in Adolescents Meets Primary Endpoint
May 27 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna and Aldevron Expanded Partnership for mRNA Vaccine and Therapeutic Pipeline
May 24 2021
Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the […]
Moderna Announces New Supply Agreement with Australia for 25 Million Doses of its COVID-19 Vaccine
May 13 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Announces New Supply Agreement with Switzerland for 7 Million Booster Vaccine Doses in 2022 and Option for Additional 7 Million Doses
May 6 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced […]
Moderna Expands Manufacturing Technology Center
May 5 2021
Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today […]
Moderna New Supply Agreement with Israel for 2022
April 21 2021
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a […]
Moderna announces FDA Authorization of Moderna COVID-19 vaccine in U.S.
December 18 2020
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines today announced that […]